Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas

Cancer

Volumn 97, Issue 9, 2003, Pages 2262-2266

  Glantz, Michael ^a   Chamberlain, Marc ^b   Liu, Qin ^c   Litofsky, N Scott ^c   Recht, Lawrence D ^c  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Elderly patients; Glioma; Radiotherapy; Temozolomide (TMZ)

Indexed keywords

TEMOZOLOMIDE;

AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER RADIOTHERAPY; CANCER SURVIVAL; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; PROGNOSIS;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COHORT STUDIES; DACARBAZINE; FEMALE; GLIOMA; HUMANS; MALE; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 0037403996     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11323     Document Type: Article

References (39)

1. Chang CH, Horton J, Schoenfeld D, et al. Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A Joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer. 1983;52:997-1007.
2. Devaux BC, O'Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. J Neurosurg. 1993;78:767-775.
3. Peschel R, Wilson L, Haffly B, et al. The effect of advanced age on the efficacy of radiation therapy for early breast cancer, local prostate cancer and grade III gliomas. Int J Radiat Oncol Biol Phys. 1993;26:539-544.
4. Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer. 1987;59:1617-1625.
5. Curran WJ, Scott CB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993;85:704-710.
6. Walker MD, Alexander E, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49:333-343.
7. Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer. 1981;47:649-652.
8. Whittle IR, Denholm SW, Gregor A. Management of patients aged over 60 years with supratentorial glioma: lessons from an audit. Surg Neurol. 1991;36:106-111.
9. Crossen JR, Garwood D, Glastein E. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol. 1994;12:627-642.
10. Rosenblum ML, Gerosa M, Dougherty DV, et al. Age-related chemosensitivity of stem cells from human malignant brain tumors. Lancet. 1982;1:885-887.
11. Shapiro WR, Shapiro JR. Biology and treatment of malignant glioma. Oncology. 1998;12:233-240.
12. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Under representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061-2067.
13. Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol. 2002;20:2109-2117.
14. Yellen SB, Cella DF, Leslie WT. Age and clinical decision making in oncology patients. J Natl Cancer Inst. 1994;86:1766-1770.
15. Newlands ES, Blackledge GR, Slack JA, et al. Phase I trial of temozolomide (CCRG 81045: M & B 39831: NSC 362856). Br J Cancer. 1992;65:287-291.
16. Yung WKA, Prados MD, YayaTur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol. 1999;17:2762-2771.
17. Yung WA, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593.
18. Gilbert MR, Friedman HS, Kuttesch JF, et al. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. Neurooncology. 2002;4:261-267.
19. Polednak AP. Time trends in incidence of brain and central nervous system cancers in Connecticut. J Natl Cancer Inst. 1991;83:1979-1981.
20. Greig NH, Ries LG, Yanick R, Rapoport SL. Increasing annual incidence of primary malignant brain tumors in the elderly. J Natl Cancer Inst. 1990;82:1621-1624.
21. Mao Y, Desmeules M, Semenciw R, et al. Increasing brain cancer rates in Canada. Can Med Assoc J. 1991;145:1583-1591.
22. Desmeules M, Mikkelsen T, Mao Y. Increasing incidence of primary malignant brain tumors: influence of diagnostic methods. J Natl Cancer Inst. 1992;84:442-445.
23. Counsell CE, Grant R. Incidence studies of primary and secondary intracranial tumors: a systematic review of their methodology and results. J Neurooncol. 1998;37:241-250.
24. Davis DL, Hoel D, Fox J, et al. International trends in cancer mortality in France, West Germany, Italy, Japan, Wales and the USA. Lancet. 1990;336:474-478.
25. Shapiro WR, Green SB, Burger PC, et al. Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma Brain Tumor Cooperative Group Trial 8001. J Neurosurg. 1989;71:1-9.
26. Wroe SJ, Foy PM, Shaw MDM, et al. Neurological and neurosurgical approaches in management of malignant brain tumors. Br Med J. 1986;293:1015-1018.
27. Cohadon F. Indications for surgery in the management of gliomas. Adv Tech Stand Neurosurg. 1990;17:189-234.
28. Shapiro WR. Therapy of adult malignant brain tumors: what have the clinical trials taught us? Semin Oncol. 1986;13:38-45.
29. Corry J, Smith JG, Wirth A, Quong G, Liew KH. Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys. 1998;41:615-620.
30. Ampil F, Fowler M, Kim K. Intracranial astrocytoma in elderly patients. J Neurooncol. 1992;12:125-130.
31. Prados MD, Levin V. Biology and treatment of malignant glioma. Semin Oncol. 2000;27 (Suppl 3):1-10.
32. Reifenberger J, Ring GU, Gies U, et al. Analysis of p53 mutation and epidermal growth factor receptor amplification in recurrent gliomas with malignant progression. J Neuropathol Exp Neurol. 1996;55:822-831.
33. Kaplan RS. Supratentorial malignant gliomas: risk patterns and therapy [editorial]. J Natl Cancer Inst. 1993;85:690-691.
34. Meckling S, Dold O, Forsyth PAJ, Brasher P, Hagen NA. Malignant supratentorial glioma in the elderly: is radiotherapy useful? Neurology. 1996;47:901-905.
35. Mohan DS, Suh JH, Phan JL, Kupelian PA, Cohen BH, Barnett GH. Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma at a tertiary care institution. Int J Radiat Oncol Biol Phys. 1998;42:981-987.
36. Villa S, Vinolas N, Verger E, et al. Efficacy of radiotherapy for malignant gliomas in elderly patients. Int J Radiat Oncol Biol Phys. 1998;42:977-980.
37. Bauman G, Gaspar L, Fisher B, et al. A histologic study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys. 1994;29:835-839.
38. Pierga JY, Hoang-Xuan K, Fuevet L, et al. Treatment of malignant gliomas in the elderly. J Neurooncol. 1999;43:187-193.
39. Fentiman IS, Tirelli U, Monfardini S. Cancer in the elderly: why so badly treated. Lancet. 1990;335:1020-1022.